Tositumomab

Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to 131I. 131I emits both beta and gamma radiation and decays with a half-life of 8 days.

Clinical trials have established the efficacy of tositumomab in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.

It is manufactured by Corixa. It sells in the U.S. under the trade name Bexxar.